Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/79218
Title: Development and Optimization of Liquid formulation of Poorly water soluble drugs
Researcher: Shah Rushil
Guide(s): Mehta Priti
Keywords: drugs
Liquid Formulation
Pharmacy
Water Soluble
University: Nirma University
Completed Date: 23-07-2015
Abstract: Drotaverine Hydrochloride Injection newlineDrotaverine hydrochloride is an antispasmodic vasodilator hypotensive drug. It is used in newlinethe treatment of functional bowel disorders and alleviating pain in renal colic. newlineCurrently, the marketed formulation of Drotaverine hydrochloride injection consists of newlineethanol as a co-solvent. Objective of present research study was to develop stable, newlineeffective and cost effective formulation without ethanol. newlineForced degradation study was performed to check stability of formulation and suitability newlineof selected analytical method. Formulation optimization was done using Quality by newlineDesign approach. The manufacturing formula and the process can be used for newlinecommercial production. Thus, the objective of formulation development of safe, stable newlineand cost effective injectable formulation of Drotaverine hydrochloride which is ethanol newlinefree is successfully accomplished. newlineNepafenac and Moxifloxacin ophthalmic suspension newlineMoxifloxacin belongs to a class of antibiotics called as fluoroquinolones. It is used to newlinetreat bacterial conjunctivitis. It works by killing the bacteria that cause infection. newlineNepafenac belongs to a class of medications called as nonsteroidal anti-inflammatory newlinedrugs (NSAIDs). Ophthalmic formulation of Nepafenac is used to treat eye pain, redness, newlineand swelling in patients who are recovering from cataract surgery. It works by inhibiting newlinethe production of certain natural substances that cause pain and swelling. newlineCurrently, there is no marketed formulation available as a combination of Nepafenac and newlineMoxifloxacin. Combination of Nepafenac and Moxifloxacin facilitates patient comfort newlineand ease of use by getting relief in a single administration. newlineThe assay of both APIs was found to be satisfactory with HPMC but, redispersibility of newlinethe formulation was not satisfactory and later was resolved by addition
Pagination: 
URI: http://hdl.handle.net/10603/79218
Appears in Departments:Institute of Pharmacy

Files in This Item:
File Description SizeFormat 
02_certificate.pdfAttached File86.18 kBAdobe PDFView/Open
03_abstract.pdf15.28 kBAdobe PDFView/Open
04_declaration.pdf178.18 kBAdobe PDFView/Open
05_acknowledgement.pdf145.07 kBAdobe PDFView/Open
06_contents.pdf32.83 kBAdobe PDFView/Open
07_list _of_tables.pdf33.09 kBAdobe PDFView/Open
08_list_of_figures.pdf22.89 kBAdobe PDFView/Open
09_abbreviation.pdf21.89 kBAdobe PDFView/Open
10_chapter1.pdf187.02 kBAdobe PDFView/Open
11_chapter2.pdf144.62 kBAdobe PDFView/Open
12_chapter3.pdf24.46 kBAdobe PDFView/Open
13_chapter4.pdf527.88 kBAdobe PDFView/Open
14_chapter5.pdf408.1 kBAdobe PDFView/Open
15_summary.pdf27.46 kBAdobe PDFView/Open
16_conclusion.pdf18.45 kBAdobe PDFView/Open
17_bibliography.pdf48.47 kBAdobe PDFView/Open
18_bibliography.pdf422.99 kBAdobe PDFView/Open
19_publication.pdf906.67 kBAdobe PDFView/Open
1_title.pdf.pdf64.83 kBAdobe PDFView/Open
20_combined all chapters.pdf13.59 MBAdobe PDFView/Open


Items in Shodhganga are protected by copyright, with all rights reserved, unless otherwise indicated.